← All trials
NCT01191801
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 17, 2010
- Primary completion
- Sep 26, 2014
- Completion date
- Mar 1, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 711
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Sunesis PharmaceuticalsLead sponsor
- Sunesis PharmaceuticalsStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.